Oncocyte Prices $29.1 Million Equity Offering
Portfolio Pulse from
Oncocyte Corp. has announced a $29.1 million equity offering to fund its transplant assay through FDA IVD clearance and commercial launch. Bio-Rad has invested to support trial and commercialization efforts.
February 10, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oncocyte Corp. has announced a $29.1 million equity offering to fund its transplant assay through FDA IVD clearance and commercial launch. Bio-Rad has invested to support trial and commercialization efforts.
The equity offering provides significant funding for Oncocyte's transplant assay, which is crucial for its FDA IVD clearance and commercial launch. The investment from Bio-Rad further supports these efforts, indicating strong backing and potential for successful commercialization.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100